Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziftomenib Combinations in AML
NCT05735184Phase 1Recruiting
- Sponsor
- Kura Oncology
- Start
- Jul 2023
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ziftomenib in acute myeloid leukemia (AML), sponsored by Kura Oncology. Primary endpoints: Rate of dose limiting toxicities at 28 days, Adverse events at 36 months and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
ziftomenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05735184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05735184.